Inauguration of Recipharm Biologics
Recipharm’s new facility for the development and manufacturing of recombinant proteins and monoclonal antibodies is formally inaugurated by recognized Swedish profiles from industry and academia including Jan Lundberg, Vice President Discovery, AstraZeneca and Professor Hans Wigzell, Karolinska Institute.
The inauguration ceremony of Recipharm Biologics takes place today in Södertälje Sweden.
Prof. Jan Lundberg, Vice President Discovery, AstraZeneca, will formally hand over the facility to Lars Backsell, chairman of the board of Recipharm. During the event, Prof. Hans Wigzell, chairman of the board of Karolinska Development is set to make a short presentation of the opportunities for biologics medicines for the treatment of diseases. Furthermore, Elisabeth Lindner, CEO, Diamyd, will give her view on the biologics landscape in Sweden from a biotech company perspective.
Recipharm AB, launched in 1995 has emerged as one of Europe's leading contract development and manufacturing organisations. The company entered the field of biologics manufacturing with the recent transfer of a majority stake in the AstraZeneca Biotech Laboratory to its new subsidiary, Recipharm Biologics AB. The transaction was completed on 1 January 2009, with Recipharm Biologics taking over the operation of the facility as an independent contract service provider for mammalian cell culture derived biopharmaceuticals.
Dr. Christel Fenge, the recently appointed General Manager of Recipharm Biologics believes that this is of significant importance for the development of biopharmaceutical drugs in Sweden. “Especially, we will focus on supporting small and medium sized biotechs and start-ups with our advanced capabilities, expertise and experience so that they can progress their ideas for the development of drugs and innovative medicines that patients are in need for. The pharmaceutical industry is a highly important for Sweden. Strengthening the capability of biotechs to develop their products and trying to keep these activities in the country is an important factor in sustaining Sweden's position in this field, both from a technological and economical perspective; not least when it comes to securing and developing future job opportunities and maintaining the country’s competitive edge in a globalised world.”
The recent acquisition of a freeze drying capability in Basel, Switzerland, together with the transfer of the AstraZeneca Biotech Laboratory enables Recipharm to offer a complete range of services for the development and manufacturing of therapeutic proteins and monoclonal antibodies from cell line development to manufacturing of investigational medicinal products, including relevant regulatory support.
Thomas Eldered, CEO and General Manager of Recipharm AB commented: “Acquiring this specialist biomanufacturing facility represents a further step towards achieving our goal of becoming one of the world’s top three contract pharmaceuticals development and manufacturing organisations.”
About Recipharm Biologics AB
Recipharm Biologics is a contract service provider supporting Pharmaceutical companies and biotechs in the development and manufacture of mammalian cell culture derived products for clinical trials. It operates from a 10.000m2 state-of-the art lab and pilot plant facility located in Södertälje, Sweden, 30km south of Stockholm. The facility holds a GMP license from the Swedish Medicinal Products Agency for the production of recombinant biological products.
Based on a 10 years track record in drug development, Recipharm Biologics offers a broad range of integrated or stand-alone services stretching from cell line development and specialist analytical services to the supply of investigational medicinal products derived from fed-batch or perfusion culture.
Recipharm is a leading contract development and manufacturing organisation based in Europe. The Company operates eight main manufacturing facilities in Sweden, France, UK and Switzerland and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with in excess of six hundred different products in multiple dosage forms that include solid dose granulates and powders, steriles, semi solids, beta-lactams, hormones and dry powder inhalers.